Influenzavirus B Infection Drug Industry Research Report 2025
Description
Summary
According to APO Research, the global Influenzavirus B Infection Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Influenzavirus B Infection Drug include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Influenzavirus B Infection Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenzavirus B Infection Drug.
The report will help the Influenzavirus B Infection Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Influenzavirus B Infection Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Influenzavirus B Infection Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Influenzavirus B Infection Drug Segment by Company
Sanofi
AbbVie Inc
Vectura Group Plc
Vaxart Inc
TSRL Inc
SK Chemicals Co Ltd
Shionogi & Co Ltd
Sanofi Pasteur SA
Romark Laboratories LC
Park Active Molecules
Novavax Inc
Mucosis BV
MedImmune LLC
Medicago Inc
Kineta Inc
Inovio Pharmaceuticals Inc
Green Cross Corp
GlaxoSmithKline Plc
Fujifilm Holdings Corporation
Daiichi Sankyo Company Ltd
ContraFect Corp
Cadila Healthcare Ltd
BioCryst Pharmaceuticals Inc
Aphios Corp
Amarillo Biosciences Inc
Altravax Inc
Adimmune Corp
Influenzavirus B Infection Drug Segment by Type
KIN-1400
GC-3106A
CF-403
APP-309
Others
Influenzavirus B Infection Drug Segment by Application
Clinic
Hospital
Others
Influenzavirus B Infection Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Influenzavirus B Infection Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Influenzavirus B Infection Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Influenzavirus B Infection Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Influenzavirus B Infection Drug include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Influenzavirus B Infection Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenzavirus B Infection Drug.
The report will help the Influenzavirus B Infection Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Influenzavirus B Infection Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Influenzavirus B Infection Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Influenzavirus B Infection Drug Segment by Company
Sanofi
AbbVie Inc
Vectura Group Plc
Vaxart Inc
TSRL Inc
SK Chemicals Co Ltd
Shionogi & Co Ltd
Sanofi Pasteur SA
Romark Laboratories LC
Park Active Molecules
Novavax Inc
Mucosis BV
MedImmune LLC
Medicago Inc
Kineta Inc
Inovio Pharmaceuticals Inc
Green Cross Corp
GlaxoSmithKline Plc
Fujifilm Holdings Corporation
Daiichi Sankyo Company Ltd
ContraFect Corp
Cadila Healthcare Ltd
BioCryst Pharmaceuticals Inc
Aphios Corp
Amarillo Biosciences Inc
Altravax Inc
Adimmune Corp
Influenzavirus B Infection Drug Segment by Type
KIN-1400
GC-3106A
CF-403
APP-309
Others
Influenzavirus B Infection Drug Segment by Application
Clinic
Hospital
Others
Influenzavirus B Infection Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Influenzavirus B Infection Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Influenzavirus B Infection Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
149 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Influenzavirus B Infection Drug Market Size (2020-2031)
- 2.2.2 Global Influenzavirus B Infection Drug Sales (2020-2031)
- 2.2.3 Global Influenzavirus B Infection Drug Market Average Price (2020-2031)
- 2.3 Influenzavirus B Infection Drug by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 KIN-1400
- 2.3.3 GC-3106A
- 2.3.4 CF-403
- 2.3.5 APP-309
- 2.3.6 Others
- 2.4 Influenzavirus B Infection Drug by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Influenzavirus B Infection Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Influenzavirus B Infection Drug Sales (K Units) of Manufacturers (2020-2025)
- 3.3 Global Influenzavirus B Infection Drug Revenue of Manufacturers (2020-2025)
- 3.4 Global Influenzavirus B Infection Drug Average Price by Manufacturers (2020-2025)
- 3.5 Global Influenzavirus B Infection Drug Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Influenzavirus B Infection Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Influenzavirus B Infection Drug, Product Type & Application
- 3.8 Global Manufacturers of Influenzavirus B Infection Drug, Established Date
- 3.9 Global Influenzavirus B Infection Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Sanofi Influenzavirus B Infection Drug Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 AbbVie Inc
- 4.2.1 AbbVie Inc Company Information
- 4.2.2 AbbVie Inc Business Overview
- 4.2.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 AbbVie Inc Influenzavirus B Infection Drug Product Portfolio
- 4.2.5 AbbVie Inc Recent Developments
- 4.3 Vectura Group Plc
- 4.3.1 Vectura Group Plc Company Information
- 4.3.2 Vectura Group Plc Business Overview
- 4.3.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio
- 4.3.5 Vectura Group Plc Recent Developments
- 4.4 Vaxart Inc
- 4.4.1 Vaxart Inc Company Information
- 4.4.2 Vaxart Inc Business Overview
- 4.4.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Vaxart Inc Influenzavirus B Infection Drug Product Portfolio
- 4.4.5 Vaxart Inc Recent Developments
- 4.5 TSRL Inc
- 4.5.1 TSRL Inc Company Information
- 4.5.2 TSRL Inc Business Overview
- 4.5.3 TSRL Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 TSRL Inc Influenzavirus B Infection Drug Product Portfolio
- 4.5.5 TSRL Inc Recent Developments
- 4.6 SK Chemicals Co Ltd
- 4.6.1 SK Chemicals Co Ltd Company Information
- 4.6.2 SK Chemicals Co Ltd Business Overview
- 4.6.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio
- 4.6.5 SK Chemicals Co Ltd Recent Developments
- 4.7 Shionogi & Co Ltd
- 4.7.1 Shionogi & Co Ltd Company Information
- 4.7.2 Shionogi & Co Ltd Business Overview
- 4.7.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio
- 4.7.5 Shionogi & Co Ltd Recent Developments
- 4.8 Sanofi Pasteur SA
- 4.8.1 Sanofi Pasteur SA Company Information
- 4.8.2 Sanofi Pasteur SA Business Overview
- 4.8.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio
- 4.8.5 Sanofi Pasteur SA Recent Developments
- 4.9 Romark Laboratories LC
- 4.9.1 Romark Laboratories LC Company Information
- 4.9.2 Romark Laboratories LC Business Overview
- 4.9.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio
- 4.9.5 Romark Laboratories LC Recent Developments
- 4.10 Park Active Molecules
- 4.10.1 Park Active Molecules Company Information
- 4.10.2 Park Active Molecules Business Overview
- 4.10.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Park Active Molecules Influenzavirus B Infection Drug Product Portfolio
- 4.10.5 Park Active Molecules Recent Developments
- 4.11 Novavax Inc
- 4.11.1 Novavax Inc Company Information
- 4.11.2 Novavax Inc Business Overview
- 4.11.3 Novavax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 Novavax Inc Influenzavirus B Infection Drug Product Portfolio
- 4.11.5 Novavax Inc Recent Developments
- 4.12 Mucosis BV
- 4.12.1 Mucosis BV Company Information
- 4.12.2 Mucosis BV Business Overview
- 4.12.3 Mucosis BV Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Mucosis BV Influenzavirus B Infection Drug Product Portfolio
- 4.12.5 Mucosis BV Recent Developments
- 4.13 MedImmune LLC
- 4.13.1 MedImmune LLC Company Information
- 4.13.2 MedImmune LLC Business Overview
- 4.13.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 MedImmune LLC Influenzavirus B Infection Drug Product Portfolio
- 4.13.5 MedImmune LLC Recent Developments
- 4.14 Medicago Inc
- 4.14.1 Medicago Inc Company Information
- 4.14.2 Medicago Inc Business Overview
- 4.14.3 Medicago Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.14.4 Medicago Inc Influenzavirus B Infection Drug Product Portfolio
- 4.14.5 Medicago Inc Recent Developments
- 4.15 Kineta Inc
- 4.15.1 Kineta Inc Company Information
- 4.15.2 Kineta Inc Business Overview
- 4.15.3 Kineta Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.15.4 Kineta Inc Influenzavirus B Infection Drug Product Portfolio
- 4.15.5 Kineta Inc Recent Developments
- 4.16 Inovio Pharmaceuticals Inc
- 4.16.1 Inovio Pharmaceuticals Inc Company Information
- 4.16.2 Inovio Pharmaceuticals Inc Business Overview
- 4.16.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.16.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
- 4.16.5 Inovio Pharmaceuticals Inc Recent Developments
- 4.17 Green Cross Corp
- 4.17.1 Green Cross Corp Company Information
- 4.17.2 Green Cross Corp Business Overview
- 4.17.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.17.4 Green Cross Corp Influenzavirus B Infection Drug Product Portfolio
- 4.17.5 Green Cross Corp Recent Developments
- 4.18 GlaxoSmithKline Plc
- 4.18.1 GlaxoSmithKline Plc Company Information
- 4.18.2 GlaxoSmithKline Plc Business Overview
- 4.18.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.18.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio
- 4.18.5 GlaxoSmithKline Plc Recent Developments
- 4.19 Fujifilm Holdings Corporation
- 4.19.1 Fujifilm Holdings Corporation Company Information
- 4.19.2 Fujifilm Holdings Corporation Business Overview
- 4.19.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.19.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio
- 4.19.5 Fujifilm Holdings Corporation Recent Developments
- 4.20 Daiichi Sankyo Company Ltd
- 4.20.1 Daiichi Sankyo Company Ltd Company Information
- 4.20.2 Daiichi Sankyo Company Ltd Business Overview
- 4.20.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.20.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio
- 4.20.5 Daiichi Sankyo Company Ltd Recent Developments
- 4.21 ContraFect Corp
- 4.21.1 ContraFect Corp Company Information
- 4.21.2 ContraFect Corp Business Overview
- 4.21.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.21.4 ContraFect Corp Influenzavirus B Infection Drug Product Portfolio
- 4.21.5 ContraFect Corp Recent Developments
- 4.22 Cadila Healthcare Ltd
- 4.22.1 Cadila Healthcare Ltd Company Information
- 4.22.2 Cadila Healthcare Ltd Business Overview
- 4.22.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.22.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio
- 4.22.5 Cadila Healthcare Ltd Recent Developments
- 4.23 BioCryst Pharmaceuticals Inc
- 4.23.1 BioCryst Pharmaceuticals Inc Company Information
- 4.23.2 BioCryst Pharmaceuticals Inc Business Overview
- 4.23.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.23.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
- 4.23.5 BioCryst Pharmaceuticals Inc Recent Developments
- 4.24 Aphios Corp
- 4.24.1 Aphios Corp Company Information
- 4.24.2 Aphios Corp Business Overview
- 4.24.3 Aphios Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.24.4 Aphios Corp Influenzavirus B Infection Drug Product Portfolio
- 4.24.5 Aphios Corp Recent Developments
- 4.25 Amarillo Biosciences Inc
- 4.25.1 Amarillo Biosciences Inc Company Information
- 4.25.2 Amarillo Biosciences Inc Business Overview
- 4.25.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.25.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio
- 4.25.5 Amarillo Biosciences Inc Recent Developments
- 4.26 Altravax Inc
- 4.26.1 Altravax Inc Company Information
- 4.26.2 Altravax Inc Business Overview
- 4.26.3 Altravax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.26.4 Altravax Inc Influenzavirus B Infection Drug Product Portfolio
- 4.26.5 Altravax Inc Recent Developments
- 4.27 Adimmune Corp
- 4.27.1 Adimmune Corp Company Information
- 4.27.2 Adimmune Corp Business Overview
- 4.27.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.27.4 Adimmune Corp Influenzavirus B Infection Drug Product Portfolio
- 4.27.5 Adimmune Corp Recent Developments
- 5 Global Influenzavirus B Infection Drug Market Scenario by Region
- 5.1 Global Influenzavirus B Infection Drug Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Influenzavirus B Infection Drug Sales by Region: 2020-2031
- 5.2.1 Global Influenzavirus B Infection Drug Sales by Region: 2020-2025
- 5.2.2 Global Influenzavirus B Infection Drug Sales by Region: 2026-2031
- 5.3 Global Influenzavirus B Infection Drug Revenue by Region: 2020-2031
- 5.3.1 Global Influenzavirus B Infection Drug Revenue by Region: 2020-2025
- 5.3.2 Global Influenzavirus B Infection Drug Revenue by Region: 2026-2031
- 5.4 North America Influenzavirus B Infection Drug Market Facts & Figures by Country
- 5.4.1 North America Influenzavirus B Infection Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Influenzavirus B Infection Drug Sales by Country (2020-2031)
- 5.4.3 North America Influenzavirus B Infection Drug Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Influenzavirus B Infection Drug Market Facts & Figures by Country
- 5.5.1 Europe Influenzavirus B Infection Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Influenzavirus B Infection Drug Sales by Country (2020-2031)
- 5.5.3 Europe Influenzavirus B Infection Drug Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Influenzavirus B Infection Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Influenzavirus B Infection Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Influenzavirus B Infection Drug Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Influenzavirus B Infection Drug Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Influenzavirus B Infection Drug Market Facts & Figures by Country
- 5.7.1 South America Influenzavirus B Infection Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Influenzavirus B Infection Drug Sales by Country (2020-2031)
- 5.7.3 South America Influenzavirus B Infection Drug Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Influenzavirus B Infection Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Influenzavirus B Infection Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Influenzavirus B Infection Drug Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Influenzavirus B Infection Drug Sales by Type (2020-2031)
- 6.1.1 Global Influenzavirus B Infection Drug Sales by Type (2020-2031) & (K Units)
- 6.1.2 Global Influenzavirus B Infection Drug Sales Market Share by Type (2020-2031)
- 6.2 Global Influenzavirus B Infection Drug Revenue by Type (2020-2031)
- 6.2.1 Global Influenzavirus B Infection Drug Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Influenzavirus B Infection Drug Revenue Market Share by Type (2020-2031)
- 6.3 Global Influenzavirus B Infection Drug Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Influenzavirus B Infection Drug Sales by Application (2020-2031)
- 7.1.1 Global Influenzavirus B Infection Drug Sales by Application (2020-2031) & (K Units)
- 7.1.2 Global Influenzavirus B Infection Drug Sales Market Share by Application (2020-2031)
- 7.2 Global Influenzavirus B Infection Drug Revenue by Application (2020-2031)
- 7.2.1 Global Influenzavirus B Infection Drug Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Influenzavirus B Infection Drug Revenue Market Share by Application (2020-2031)
- 7.3 Global Influenzavirus B Infection Drug Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Influenzavirus B Infection Drug Value Chain Analysis
- 8.1.1 Influenzavirus B Infection Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Influenzavirus B Infection Drug Production Mode & Process
- 8.2 Influenzavirus B Infection Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Influenzavirus B Infection Drug Distributors
- 8.2.3 Influenzavirus B Infection Drug Customers
- 9 Global Influenzavirus B Infection Drug Analyzing Market Dynamics
- 9.1 Influenzavirus B Infection Drug Industry Trends
- 9.2 Influenzavirus B Infection Drug Industry Drivers
- 9.3 Influenzavirus B Infection Drug Industry Opportunities and Challenges
- 9.4 Influenzavirus B Infection Drug Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Influenzavirus B Infection Drug Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Influenzavirus B Infection Drug Sales (K Units) of Manufacturers (2020-2025)
- Table 7. Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Influenzavirus B Infection Drug Revenue of Manufacturers (2020-2025)
- Table 9. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Influenzavirus B Infection Drug Average Price (US$/Unit) of Manufacturers (2020-2025)
- Table 11. Global Influenzavirus B Infection Drug Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Influenzavirus B Infection Drug, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Influenzavirus B Infection Drug, Product Type & Application
- Table 14. Global Influenzavirus B Infection Drug Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Influenzavirus B Infection Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Sanofi Company Information
- Table 19. Sanofi Business Overview
- Table 20. Sanofi Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 21. Sanofi Influenzavirus B Infection Drug Product Portfolio
- Table 22. Sanofi Recent Developments
- Table 23. AbbVie Inc Company Information
- Table 24. AbbVie Inc Business Overview
- Table 25. AbbVie Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 26. AbbVie Inc Influenzavirus B Infection Drug Product Portfolio
- Table 27. AbbVie Inc Recent Developments
- Table 28. Vectura Group Plc Company Information
- Table 29. Vectura Group Plc Business Overview
- Table 30. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 31. Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio
- Table 32. Vectura Group Plc Recent Developments
- Table 33. Vaxart Inc Company Information
- Table 34. Vaxart Inc Business Overview
- Table 35. Vaxart Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 36. Vaxart Inc Influenzavirus B Infection Drug Product Portfolio
- Table 37. Vaxart Inc Recent Developments
- Table 38. TSRL Inc Company Information
- Table 39. TSRL Inc Business Overview
- Table 40. TSRL Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 41. TSRL Inc Influenzavirus B Infection Drug Product Portfolio
- Table 42. TSRL Inc Recent Developments
- Table 43. SK Chemicals Co Ltd Company Information
- Table 44. SK Chemicals Co Ltd Business Overview
- Table 45. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 46. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio
- Table 47. SK Chemicals Co Ltd Recent Developments
- Table 48. Shionogi & Co Ltd Company Information
- Table 49. Shionogi & Co Ltd Business Overview
- Table 50. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 51. Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio
- Table 52. Shionogi & Co Ltd Recent Developments
- Table 53. Sanofi Pasteur SA Company Information
- Table 54. Sanofi Pasteur SA Business Overview
- Table 55. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 56. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio
- Table 57. Sanofi Pasteur SA Recent Developments
- Table 58. Romark Laboratories LC Company Information
- Table 59. Romark Laboratories LC Business Overview
- Table 60. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 61. Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio
- Table 62. Romark Laboratories LC Recent Developments
- Table 63. Park Active Molecules Company Information
- Table 64. Park Active Molecules Business Overview
- Table 65. Park Active Molecules Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 66. Park Active Molecules Influenzavirus B Infection Drug Product Portfolio
- Table 67. Park Active Molecules Recent Developments
- Table 68. Novavax Inc Company Information
- Table 69. Novavax Inc Business Overview
- Table 70. Novavax Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 71. Novavax Inc Influenzavirus B Infection Drug Product Portfolio
- Table 72. Novavax Inc Recent Developments
- Table 73. Mucosis BV Company Information
- Table 74. Mucosis BV Business Overview
- Table 75. Mucosis BV Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 76. Mucosis BV Influenzavirus B Infection Drug Product Portfolio
- Table 77. Mucosis BV Recent Developments
- Table 78. MedImmune LLC Company Information
- Table 79. MedImmune LLC Business Overview
- Table 80. MedImmune LLC Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 81. MedImmune LLC Influenzavirus B Infection Drug Product Portfolio
- Table 82. MedImmune LLC Recent Developments
- Table 83. Medicago Inc Company Information
- Table 84. Medicago Inc Business Overview
- Table 85. Medicago Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 86. Medicago Inc Influenzavirus B Infection Drug Product Portfolio
- Table 87. Medicago Inc Recent Developments
- Table 88. Kineta Inc Company Information
- Table 89. Kineta Inc Business Overview
- Table 90. Kineta Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 91. Kineta Inc Influenzavirus B Infection Drug Product Portfolio
- Table 92. Kineta Inc Recent Developments
- Table 93. Inovio Pharmaceuticals Inc Company Information
- Table 94. Inovio Pharmaceuticals Inc Business Overview
- Table 95. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 96. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
- Table 97. Inovio Pharmaceuticals Inc Recent Developments
- Table 98. Green Cross Corp Company Information
- Table 99. Green Cross Corp Business Overview
- Table 100. Green Cross Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 101. Green Cross Corp Influenzavirus B Infection Drug Product Portfolio
- Table 102. Green Cross Corp Recent Developments
- Table 103. GlaxoSmithKline Plc Company Information
- Table 104. GlaxoSmithKline Plc Business Overview
- Table 105. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 106. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio
- Table 107. GlaxoSmithKline Plc Recent Developments
- Table 108. Fujifilm Holdings Corporation Company Information
- Table 109. Fujifilm Holdings Corporation Business Overview
- Table 110. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 111. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio
- Table 112. Fujifilm Holdings Corporation Recent Developments
- Table 113. Daiichi Sankyo Company Ltd Company Information
- Table 114. Daiichi Sankyo Company Ltd Business Overview
- Table 115. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 116. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio
- Table 117. Daiichi Sankyo Company Ltd Recent Developments
- Table 118. ContraFect Corp Company Information
- Table 119. ContraFect Corp Business Overview
- Table 120. ContraFect Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 121. ContraFect Corp Influenzavirus B Infection Drug Product Portfolio
- Table 122. ContraFect Corp Recent Developments
- Table 123. Cadila Healthcare Ltd Company Information
- Table 124. Cadila Healthcare Ltd Business Overview
- Table 125. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 126. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio
- Table 127. Cadila Healthcare Ltd Recent Developments
- Table 128. BioCryst Pharmaceuticals Inc Company Information
- Table 129. BioCryst Pharmaceuticals Inc Business Overview
- Table 130. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 131. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
- Table 132. BioCryst Pharmaceuticals Inc Recent Developments
- Table 133. Aphios Corp Company Information
- Table 134. Aphios Corp Business Overview
- Table 135. Aphios Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 136. Aphios Corp Influenzavirus B Infection Drug Product Portfolio
- Table 137. Aphios Corp Recent Developments
- Table 138. Amarillo Biosciences Inc Company Information
- Table 139. Amarillo Biosciences Inc Business Overview
- Table 140. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 141. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio
- Table 142. Amarillo Biosciences Inc Recent Developments
- Table 143. Altravax Inc Company Information
- Table 144. Altravax Inc Business Overview
- Table 145. Altravax Inc Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 146. Altravax Inc Influenzavirus B Infection Drug Product Portfolio
- Table 147. Altravax Inc Recent Developments
- Table 148. Adimmune Corp Company Information
- Table 149. Adimmune Corp Business Overview
- Table 150. Adimmune Corp Influenzavirus B Infection Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 151. Adimmune Corp Influenzavirus B Infection Drug Product Portfolio
- Table 152. Adimmune Corp Recent Developments
- Table 153. Global Influenzavirus B Infection Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 154. Global Influenzavirus B Infection Drug Sales by Region (2020-2025) & (K Units)
- Table 155. Global Influenzavirus B Infection Drug Sales Market Share by Region (2020-2025)
- Table 156. Global Influenzavirus B Infection Drug Sales by Region (2026-2031) & (K Units)
- Table 157. Global Influenzavirus B Infection Drug Sales Market Share by Region (2026-2031)
- Table 158. Global Influenzavirus B Infection Drug Revenue by Region (2020-2025) & (US$ Million)
- Table 159. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2020-2025)
- Table 160. Global Influenzavirus B Infection Drug Revenue by Region (2026-2031) & (US$ Million)
- Table 161. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2026-2031)
- Table 162. North America Influenzavirus B Infection Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 163. North America Influenzavirus B Infection Drug Sales by Country (2020-2025) & (K Units)
- Table 164. North America Influenzavirus B Infection Drug Sales by Country (2026-2031) & (K Units)
- Table 165. North America Influenzavirus B Infection Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 166. North America Influenzavirus B Infection Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 167. Europe Influenzavirus B Infection Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 168. Europe Influenzavirus B Infection Drug Sales by Country (2020-2025) & (K Units)
- Table 169. Europe Influenzavirus B Infection Drug Sales by Country (2026-2031) & (K Units)
- Table 170. Europe Influenzavirus B Infection Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 171. Europe Influenzavirus B Infection Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 172. Asia Pacific Influenzavirus B Infection Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 173. Asia Pacific Influenzavirus B Infection Drug Sales by Country (2020-2025) & (K Units)
- Table 174. Asia Pacific Influenzavirus B Infection Drug Sales by Country (2026-2031) & (K Units)
- Table 175. Asia Pacific Influenzavirus B Infection Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 176. Asia Pacific Influenzavirus B Infection Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 177. South America Influenzavirus B Infection Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 178. South America Influenzavirus B Infection Drug Sales by Country (2020-2025) & (K Units)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
